Overview
Lobbying Costs
None declared
None declared
Lobbyists (Full time equivalent)
1 Fte (3)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Baxalta Incorporated (Baxalta)
EU Transparency Register
725783918528-37 First registered on 04 Sep 2015
Goals / Remit
baxalta is a global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology.
Main EU files targeted
All initiatives, policies, and legislative files related to the biopharmaceutical sector with particular focus on hematology, immunology and oncology . Topics include personalised medicines, orphan drugs, patient access to innovative medicines, R&D, clinical trials, HTA, biosimilars, pharmaceutical legislation, EU Falsified Medicines directive, Blood Directive.
Address
Head Office
1200 Lakeside Drive
Bannockburn, Illinois
UNITED STATESEU Office
boulevard d'Angleterre 2-4
Braine l'Alleud
BELGIUM -
People
Total lobbyists declared
3
Employment time Lobbyists 50% 1 25% 2 Lobbyists (Full time equivalent)
1
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 06 May 2024
Name Start date End Date Toon DIGNEFFE 28 Oct 2015 02 Sep 2016 Ms Astrid Jankowitsch 28 Oct 2015 02 Sep 2016 Ms Maria Joaquina RODRIGUEZ SANCHEZ 13 Oct 2015 02 Sep 2016 Ms Joaquina Maria RODRIGUEZ SANCHEZ 10 Oct 2015 20 Oct 2015 Complementary Information
While several Baxalta employees contribute to the company’s activities falling under the scope of the Transparency Register, only 3 employees spend more than 10% of their respective work time on this: Toon Digneffe, Astrid Jankowitsch, Maria Rodriguez Sanchez
Person in charge of EU relations
Mr Toon Digneffe (Head of Patient and Innovation Policy)
Person with legal responsibility
Mr Ludwig N Hantson (CEO)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
EFPIA, EBE, Europabio, PPTA, Amcham EU, EBG
Member organisations
None declared
-
Financial Data
Closed financial year
None declared
Lobbying costs for closed financial year
None declared
Other financial info
this amount is based on an estimate of costs for the period from July 1st, 2015 till December 31, 2015 as Baxalta started as an independent biopharmaceutical company as of July 1st, 2015. Information might be further updated to reflect the ongoing changes since the company creation on July 1st, 2015.
In order to avoid double reporting, this figure does not include trade association memberships.
The estimate has been done following the updated Transparency Register Implementation Guidelines and is consistent with the guidance provided by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
-
EU Structures
Groups (European Commission)
None
ACC
None
Groups (European Parliament)
None
Communication activities
The revision of the implementing guidelines on orphan drug designation; the follow-up actions of Council recommendations on an action in the field of rare diseases (2009/C 151/02); the setting-up of the European Commission initiative on rare cancers; the implementation of the Clinical Trials Regulation (536/2014); the debates and initiatives on international reference pricing of medicines; European cooperation mechanisms on Health Technology Assessment (eg EUnetHTA).
Other activities
Baxalta started as an independent biopharmaceutical company as of July 1st, 2015. Information might be further updated to reflect the ongoing changes since the company creation on July 1st, 2015.
Meetings
Meetings
None declared